Debiopharm International SA clinical trials

A subsidiary of Debiopharm

The registry lists 51 studies whose lead sponsor is Debiopharm International SA. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 51. List all 51 → · All Debiopharm studies →

• A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)RecruitingNCT06969430Phase 1/2

  Sponsor listed in the registry: Debiopharm International SA

• A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin AnalogsRecruitingNCT06930625Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed GlioblastomaRecruitingNCT05765812Phase 1/2

  Sponsor listed in the registry: Debiopharm International SA

• Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid TumorsRecruitingNCT04855656Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of Debio 1453P in Healthy AdultsRecruitingNCT07035769Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Renal Impairment Pharmacokinetics (PK) Trial of AfabicinNot yet recruitingNCT07758608Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)Active, not recruitingNCT06129539Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to StaphylococcusTerminatedNCT03723551Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate CancerCompletedNCT06395753Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid TumorsTerminatedNCT05109975Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based TherapyTerminatedNCT05815160Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Study of RP-6306 With FOLFIRI in Advanced Solid TumorsTerminatedNCT05147350Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Study of RP-6306 With Gemcitabine in Advanced Solid TumorsTerminatedNCT05147272Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid TumorsTerminatedNCT03968653Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedNCT05364944Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLCompletedNCT02564744Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)TerminatedNCT03834220Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143CompletedNCT04122625Phase 1/2

  Sponsor listed in the registry: Debiopharm International SA

• Debio 1143-201 Dose-finding and Efficacy Phase I/II TrialCompletedNCT02022098Not applicable

  Sponsor listed in the registry: Debiopharm International SA

• A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based TherapyCompletedNCT03270176Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male ParticipantsCompletedNCT04962724Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) AlterationsTerminatedNCT01948297Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Study of Debio 1450 for Bacterial Skin InfectionsCompletedNCT02426918Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT01078649Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy SubjectsCompletedNCT03209648Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement SurgeryCompletedNCT02726438Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious PubertyCompletedNCT01467882Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedNCT01446250Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionCompletedNCT02094443Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve ParticipantsCompletedNCT01318694Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve ParticipantsCompletedNCT01215643Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C PatientsCompletedNCT02753699Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous TreatmentCompletedNCT01183169Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy SubjectsCompletedNCT01975337Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedNCT01500772Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy SubjectsCompletedNCT01860326Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsCompletedNCT01970904Not applicable

  Sponsor listed in the registry: Debiopharm International SA

• Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid MalignanciesTerminatedNCT01930292Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNCT00854802Not applicable

  Sponsor listed in the registry: Debiopharm International SA

• A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard TreatmentCompletedNCT00537407Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male SubjectsCompletedNCT02595203Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate CancerCompletedNCT01656161Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]TerminatedNCT01714037Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy VolunteersCompletedNCT02214433Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's DiseaseCompletedNCT00423228Not applicable

  Sponsor listed in the registry: Debiopharm International SA

• A Single Dose Study of Debio 1450 in Healthy SubjectsCompletedNCT02162199Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart FailureWithdrawnNCT00869115Phase 1

  Sponsor listed in the registry: Debiopharm International SA

• Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure PatientsWithdrawnNCT00838253Phase 2

  Sponsor listed in the registry: Debiopharm International SA

• Efficacy and Safety of a Triptorelin 6-month Formulation in Patients With Advanced Prostate CancerCompletedNCT00751790Phase 3

  Sponsor listed in the registry: Debiopharm International SA

• Study of Debio 0932 in Patients With Advanced Solid Tumours or LymphomaCompletedNCT01168752Phase 1

  Sponsor listed in the registry: Debiopharm International SA